VIR’s Scangos Retires, Pliant’s IPF Win, & Some Painful Decisions
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Your Edge In Biotech.
Frontpoints Latest Articles
Concert Gets Acquired, Structure Tees Up IPO, & a Proposed Noncompete Ban
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
JPM Vibes, Verily Cuts Back, & Eisai’s Transparent Price
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
J&J Walks Away from Fate, Century Cuts Back, & Moderna’s Strategic Buy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward... Read More
Madrigal’s NASH Persistence Pays, Gilead’s Mixed TIGIT Bag, & Zymeworks’ Rebound
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Amgen Buys Horizon, Mirati’s KRAS Drug OK, & Nimbus’s Tyk2 Windfall
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Summit’s Bold Bid, Karuna’s Commercial Boss, & Gossamer’s Stumble
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More
Alzheimer’s Debate, Nimbus to Challenge BMS, & a Microbiome First
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward... Read More